CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER²⁺ Breast Cancer
- PMID: 26977873
- DOI: 10.1016/j.ccell.2016.02.016
CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER²⁺ Breast Cancer
Abstract
CDK4/6 inhibitors have received approval for treating hormone-positive breast tumors, but whether other aggressive cancers respond to these molecules is not yet clear. In this issue of Cancer Cell, Goel et al. (2016) report an unexpected activity of CDK4/6 inhibitors in reducing mTOR function and re-sensitizing HER2-positive cancers to EGFR/HER2 blockade.
Copyright © 2016 Elsevier Inc. All rights reserved.
Comment on
-
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.Cancer Cell. 2016 Mar 14;29(3):255-269. doi: 10.1016/j.ccell.2016.02.006. Cancer Cell. 2016. PMID: 26977878 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous